Omeprazole delayed-release capsules in combination with other medications are used to eliminate H. pylori, a bacteria causing ulcers and prevent the development of new ulcers in people with a history of ulcer formation of the small intestine. Prescription omeprazole is also used to treat higher acid producing stomach conditions such as Zollinger-Ellison syndrome in adults. According to the survey by Clinical Gastroenterology and Hepatology, 2012, ZES occurs in about one in every 1 million people, and is more common among men 30 to 50 years old.
Market Dynamics
Increasing prevalence of acid related diseases (ARDs) including gastroesophageal reflux disease (GERD) is a major factor driving omeprazole market growth. According to the research survey conducted by Florida Hospitals, 2015, pregnant women are at a higher risk of acid reflux, with an estimated 25% pregnant women experiencing the symptoms. The survey further stated that about 20% of people with acid reflux are at a higher risk of developing gastroesophageal reflux disease (GERD). Furthermore, increase in H.pylori infection and NSAID associated gastric and duodenal ulcers are expected to bolster market growth in the near future.
Also, launch of low-cost generic versions of omeprazole is expected to fuel market growth. For instance, in 2016, Dr. Reddy’s launched generic version to Zegerid capsules (omeprazole/sodium bicarbonate) for short-term treatment of stomach and duodenal ulcers, erosive esophagitis and heartburn associated with gastroesophageal reflux disease (GERD).
Key features of the study:
- This report provides in-depth analysis of the omeprazole market and provides market size (US$ million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017, as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
- It profiles key players in the global omeprazole market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include, Astrazeneca Plc., Sandoz, Inc., Mylan N.V., Apotex, Inc., Dr. Reddy’s Laboratories, Inc., Impax Laboratories, Inc., Perrigo Company Plc., Santarus, Inc., Watson laboratories, Inc., and Lek Pharmaceuticals d.d.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
- The global omeprazole market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the omeprazole market
Detailed Segmentation:
- Global Omeprazole Market, By Dosage Form:
- Global Omeprazole Market, By Indication:
- Duodenal Ulcer
- Gastric Ulcer
- Gastroesophageal Reflux Disease (GERD)
- Erosive Esophagitis
- Others
- Global Omeprazole Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Omeprazole Market, By Geography:
- North America
- By Dosage Form:
- By Indication:
- Duodenal Ulcer
- Gastric Ulcer
- Gastroesophageal Reflux Disease (GERD)
- Erosive Esophagitis
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Dosage Form:
- By Indication:
- Duodenal Ulcer
- Gastric Ulcer
- Gastroesophageal Reflux Disease (GERD)
- Erosive Esophagitis
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Dosage Form:
- By Indication:
- Duodenal Ulcer
- Gastric Ulcer
- Gastroesophageal Reflux Disease (GERD)
- Erosive Esophagitis
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Dosage Form:
- By Indication:
- Duodenal Ulcer
- Gastric Ulcer
- Gastroesophageal Reflux Disease (GERD)
- Erosive Esophagitis
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Dosage Form:
- By Indication:
- Duodenal Ulcer
- Gastric Ulcer
- Gastroesophageal Reflux Disease (GERD)
- Erosive Esophagitis
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Dosage Form:
- By Indication:
- Duodenal Ulcer
- Gastric Ulcer
- Gastroesophageal Reflux Disease (GERD)
- Erosive Esophagitis
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Astrazeneca Plc. *
- Company Overview
- Product Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Sandoz, Inc.
- Mylan N.V.
- Apotex, Inc.
- Reddy’s Laboratories Inc.
- Impax laboratories, Inc.
- Perrigo Company Plc.
- Santarus, Inc.
- Watson Laboratories, Inc.
- Lek Pharmaceuticals d.d.
“*” marked represents similar segmentation in other categories in the respective section.
